Agafi Intravitreal Injection
Aflibercept
2 mg/0.05 ml
Incepta Pharmaceuticals Ltd.
| Pack size | 1's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 32000.00 AED |
Indications
Agafi Intravitreal Injection is used for:
Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Macular Edema Following Retinal Vein Occlusion (RVO)
• Diabetic Macular Edema (DME)
• Diabetic Retinopathy (DR)
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Ocular or periocular infection
• Active intraocular inflammation
• Hypersensitivity
Precautions
•Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
• Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.
• There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors
Pregnancy-Lactation
Pregnancy: Adequate and well-controlled studies with Aflibercept have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations
Lactation: There is no information regarding the presence of aflibercept in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production/excretion.
Females and Males of Reproductive Potential:
Contraception: Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last intravitreal injection of Aflibercept.
Infertility: There are no data regarding the effects of Aflibercept on human fertility
Interactions
Adverse Effects
Side effects of Aflibercept :
The most common adverse reactions (≥5%) reported in patients receiving Aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Mechanism of Action
Aflibercept works as a decoy receptor that traps vascular endothelial growth factors (VEGF-A, VEGF-B, PlGF) to block their ability to stimulate abnormal blood vessel growth (angiogenesis) and leakage in the eye, treating conditions like wet AMD and diabetic macular edema by reducing vascular permeability and new vessel formation.
Note
Agafi 2 mg/0.05 ml Intravitreal Injection manufactured by Incepta Pharmaceuticals Ltd.. Its generic name is Aflibercept. Agafi is availble in Bangladesh.
Farmaco BD drug index information on Agafi Intravitreal Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.